Interview of Michael Chan for RTHKsimonc2iMay 12, 20211 min readRTHK came to C2i to ask Dr Michael Chan questions about his recent breakthrough study on Simeprevir as a potent treatment for COVID19. Full link to the publication
C2i and C2iTech Join Forces with Jingke to Establish a Cross-Border Strategic Partnership Focused on Patient-Derived Organoids for Personalized Oncology Solutions
C2i and Hitachi Celebrating Innovation: Launch of Hong Kong's First Automatic Organoid Culture System and New Collaborations in 3D-Printed Airway Organoids
